Core Insights - Daxor Corporation has published a significant case series in JACC: Case Reports, highlighting the importance of blood volume analysis in heart failure treatment, identifying a specific phenotype characterized by expanded blood volume overload and elevated red blood cells [1][2] - The study evaluated 179 advanced heart failure patients, revealing that 20% (36 patients) exhibited the hypervolemia/polycythemia phenotype, with four patients undergoing therapeutic phlebotomy [2][5] Company Overview - Daxor Corporation (NASDAQ:DXR) is a leader in blood volume measurement technology, known for its BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - Over 65,000 tests have been conducted at major U.S. hospitals, significantly improving outcomes in heart failure and critical care by reducing mortality and readmissions [3] Clinical Findings - The BVA analysis detected critical volume issues that standard blood tests missed, affecting 700,000 to 1,400,000 heart failure patients in the U.S. [5] - Patients with the identified phenotype face worse clinical outcomes, including higher risks of stroke and blood clots if untreated [5] - Therapeutic phlebotomy guided by BVA resulted in significant symptom improvement with no hospitalizations or deaths over a 12-month period [5]
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment